ERBB2 and breast carcinoma: The prognostic power of CDH10 was further evaluated by investigating its association with relapse-free survival in the different breast cancer molecular subtypes, or intrinsic subtypes, Luminal A and Luminal B for the ER+ tumors and HER2+ and basal-like for the ER- tumors (Figures 5D-G).